Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry J Sacks

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 7, 2026
Long-term efficacy and safety of dupilumab in patients enrolled from Latin American centers from the open-label extension LIBERTY ASTHMA TRAVERSE studyAbraham Alí Munive, Marco Antonio Fernández Corzo, Adrián Rendón, et al.
The Journal of Allergy and Clinical Immunology. Global|June 12, 2026
The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammationWilliam W Busse, Melissa Iammatteo, Mena Soliman, et al.
American Journal of Respiratory and Critical Care Medicine|October 28, 2025
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE TrialCeleste Porsbjerg, Eleanor M Dunican, Njira L Lugogo, et al.
The Lancet. Respiratory Medicine|February 13, 2025
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trialMario Castro, Alberto Papi, Celeste Porsbjerg, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 7, 2026
Long-term efficacy and safety of dupilumab in patients enrolled from Latin American centers from the open-label extension LIBERTY ASTHMA TRAVERSE studyAbraham Alí Munive, Marco Antonio Fernández Corzo, Adrián Rendón, et al.
The Journal of Allergy and Clinical Immunology. Global|June 12, 2026
The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammationWilliam W Busse, Melissa Iammatteo, Mena Soliman, et al.
American Journal of Respiratory and Critical Care Medicine|October 28, 2025
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE TrialCeleste Porsbjerg, Eleanor M Dunican, Njira L Lugogo, et al.
The Lancet. Respiratory Medicine|February 13, 2025
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trialMario Castro, Alberto Papi, Celeste Porsbjerg, et al.
Pageof 2